Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

compulsory licenses

Bristol-Myers Squibb (BMS) building

Opdivo plus Yervoy effective first-line in lung cancer

Study shows immuno-oncology agents work well together

Bristol-Myers Squibb (BMS) building

BMS’ myeloma treatment accepted for priority review

If approved elotuzumab will be marketed as Empliciti

- PMLiVE

Anti-hypertensive market to slow in Asia-Pacific

New data shows the value will approach $20bn 2021

- PMLiVE

Opdivo approved via UK’s early drug access scheme

Bristol-Myers Squibb’s immunotherapy the first lung cancer drug approved by EAMS

Eli Lilly HQ

Lilly and Immunocore ink immunotherapy R&D deal

Firms will test new joint therapy in patients with melanoma

- PMLiVE

Ten new medicines recommended in Europe

Includes double approvals for rare disease specialist Alexion and Novartis

- PMLiVE

BMS drops antiviral research in R&D shake-up

Up to 100 positions set to be lost by the US company’s research shift

Roche Basel Switzerland

Roche maintains dominance as leading cancer drugmaker

But the firm’s growth is stalling as pricing pressures hit sales

Daiichi Sankyo logo

Daiichi Sankyo offloads stake in India’s Sun Pharma

Japanese firm wants to shed its share of the generic Indian drugmaker

Bristol-Myers Squibb (BMS) building

BMS hails Opdivo and Yervoy combo in melanoma

New PD-1 therapy shines against the world’s first immunotherapy for skin cancer

Gilead Sciences

Sovaldi pushes Gilead to the top of US pharma list

Blockbuster hep c pill sees the firm go from fourteenth to first in just one year

Bristol-Myers Squibb (BMS) building

BMS buys into gene therapy with $1bn uniQure alliance

US firm on a deal spree in 2015 as it racks up yet another collaboration

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links